L2M: Business Strategy for ECM-Plate—A Next-Generation 3D Tissue Model for Lung Fibrosis

This proposal focuses on developing a detailed commercialization strategy for a next-generation 3D tissue culture technology aimed at addressing key challenges in lung disease research. While advanced 3D culture methods can more accurately represent human physiology than traditional approaches, many of these systems remain expensive, complicated, or heavily reliant on specialized infrastructure. By contrast, our platform is designed to be a user-friendly, shelf-stable system that can be readily integrated into standard lab workflows, replicating relevant lung microenvironments for drug testing and tissue modeling. During this work, we will conduct market segmentation and competitive analysis, ensuring the product’s unique advantages—ease of use, mechanical tunability, and compatibility with standard plates—are aligned with real-world demands. The intern will also refine manufacturing workflows, quality-control checkpoints, and a financial model to guide pricing, budgeting, and potential revenue streams. This thorough planning will enable a structured product launch that attracts pilot customers and interested industry partners. Broader impacts of this proposal include reducing the need for animal testing, which is ethically and logistically burdensome, and enhancing Canada’s capacity in biomedical innovation. By outlining a clear route to commercialization, the project may foster specialized job opportunities in biotech and attract further investments in advanced cell culture technologies.

Faculty Supervisor:

Jeremy Hirota

Student:

Partner:

DMZ Ventures Inc

Discipline:

Life Sciences

Sector:

Biotechnology; Life Sciences (not health)

University:

McMaster University

Program: